Three‐month posttreatment prostate‐specific antigen level as a biomarker of treatment response in patients with intermediate‐risk or high‐risk prostate cancer treated with androgen deprivation therapy and radiotherapy

Cancer, EarlyView.


https://ift.tt/2HWXXLV